Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

References

• Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17:2533–2545.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–549.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195–200.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976–4984.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, San Miguel JF, Jagannath S, et al. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18:2145–2163.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Lannert H, Bommer J, et al. Multiple myeloma and renal failure. Nephrol Dial Transplant. 2000;15:301–304.
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65:175–181.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Rossou M, Gkotzmanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423–429.
   PubMed Web of Science ®Google Scholar
• Uttervall K, Duru AD, Lund J, et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One. 2014;9:e101819.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia. 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Corradini P, et al. The STRATUS (MM-010) trial: a single-arm, phase 3B study evaluating safety and efficacy of pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Haematologica. 2015;100:(Supplement). Abstract 273.
   Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826–1832.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
   PubMed Web of Science ®Google Scholar
• Pomalyst (pomalidomide) [package insert]. Summit, NJ: Celgene Corporation; 2015.
   Google Scholar
• Imnovid (pomalidomide) [summary of product characteristics]. Uxbridge, UK: Celgene Europe; 2015.
   Google Scholar
• Botev R, Mallie JP, Wetzels JF, et al. The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. Clin J Am Soc Nephrol. 2011;6:937–950.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466–1475.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Christoulas D, Roussou M, et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010;85:1–5.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013;71:489–501.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Weisel KC, Dimopoulos MA, Moreau P, et al. Analysis of MM-003 patients with moderate renal impairment using pomalidomide + low-dose dexamethasone (POM + LoDEX) vs. high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Haematologica. 2013;98:(Supplement). Abstract 244.
   Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121:1968–1975.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121:1961–1967.
   PubMed Web of Science ®Google Scholar
• Weisel K, Dimopoulos M, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). J Clin Oncol. 2013;31:(Supplement). Abstract 8527.
   Google Scholar
• Siegel DS, Richardson PG, Baz R, et al. Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM): impact of renal function on patient outcomes. Blood. 2012;120:(Supplement). Abstract 4072.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–1585.
   PubMed Web of Science ®Google Scholar
• Matous J, Siegel D, Lonial S, et al. MM-008: a phase 1 trial evaluating pharmacokinetics and tolerability of pomalidomide + low-dose dexamethasone in patients with relapsed or refractory and refractory multiple myeloma and renal impairment. Blood. 2014;124:(Supplement). Abstract 4730.
   Web of Science ®Google Scholar
• Sonneveld P, Heyne N, Kueenburg E, et al. MM-013: an ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI), including patients (pts) undergoing hemodialysis. J Clin Oncol. 2014;32:TPS8626.
   Google Scholar